We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: capecitabine
MedXY News
EnglishTag

capecitabine

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

A Decadel Leap: TCX Regimen Outperforms Standard TAC in 10-Year Survival for High-Risk HER2-Negative Breast Cancer
newsadjuvant chemotherapycapecitabine

A Decadel Leap: TCX Regimen Outperforms Standard TAC in 10-Year Survival for High-Risk HER2-Negative Breast Cancer

By MedXY|Jan 14, 2026

A 10-year randomized trial reveals that replacing anthracyclines with capecitabine (TCX) significantly improves overall survival and reduces toxicity compared to the standard TAC regimen in high-risk, HER2-negative breast cancer patients.

Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits
newscapecitabineFOXC1

Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits

By MedXY|Nov 30, 2025

A 10‑year follow‑up of SYSUCC‑001 shows 1 year of metronomic capecitabine after standard adjuvant therapy improved disease‑free survival in early triple‑negative breast cancer; FOXC1 expression emerged as a potential predictive biomarker in

Clinical Updatescapecitabine

Methylcobalamin Significantly Reduces Severe Hand-Foot Syndrome in HER2 Negative Early Breast Cancer Patients Receiving Capecitabine: Results from a Phase 3 Randomised Trial

By MedXY|Oct 8, 2025

Oral methylcobalamin notably decreased the incidence of grade ≥2 hand-foot syndrome in patients with HER2 negative early breast cancer undergoing adjuvant capecitabine treatment, without added safety concerns, improving treatment adherence

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities